WASHINGTON – Treatment with investigational mavacamten allowed patients with advanced obstructive hypertrophic cardiomyopathy (oHCM) to avoid septal reduction therapies (SRT), a researcher reported. In the VALOR-HCM study among 56 patients with ...
from Google Alert - health https://ift.tt/mcK1uDo
via IFTTT
0 comments:
Post a Comment